We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$923M
Cap. Flow
+$224M
Cap. Flow %
2.14%
Top 10 Hldgs %
34.54%
Holding
153
New
17
Increased
27
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$170M
2
AET
Aetna Inc
AET
+$79.5M
3
UHS icon
Universal Health Services
UHS
+$75.3M
4
KALA icon
KALA BIO
KALA
+$52.2M
5
IMMU
Immunomedics Inc
IMMU
+$50.5M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$185M
2
EW icon
Edwards Lifesciences
EW
+$51.3M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$50.6M
4
INSM icon
Insmed
INSM
+$48M
5
GKOS icon
Glaukos
GKOS
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.18%
2 Financials 2.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYK icon
51
Stryker
SYK
$135B
$59.8M 0.57%
421,000
+104,700
+33% +$15M
ISRG icon
52
Intuitive Surgical
ISRG
$128B
$59M 0.56%
507,600
+73,800
+17% +$8.04M
ACHN
53
DELISTED
Achillion Pharmaceuticals
ACHN
$58.7M 0.56%
13,062,900
-44,300
-0.3% -$197K
INSM icon
54
Insmed
INSM
$22.5B
$58.5M 0.56%
1,875,016
-2,518,493
-57% -$48M
GWPH
55
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$56.9M 0.54%
561,071
– –
BMY icon
56
Bristol-Myers Squibb
BMY
$130B
$55.8M 0.53%
874,700
– –
IART icon
57
Integra LifeSciences
IART
$1.39B
$55.1M 0.53%
1,090,910
+664,000
+156% +$34.1M
MNK
58
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$55M 0.53%
1,472,700
– –
INSY
59
DELISTED
Insys Therapeutics, Inc.
INSY
$54.8M 0.52%
6,171,440
– –
VRAY
60
DELISTED
ViewRay, Inc.
VRAY
$54.5M 0.52%
9,458,567
– –
KALA icon
61
KALA BIO
KALA
$11.7M
$54.3M 0.52%
+951
New +$52.2M
LKFT
62
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$53.3M 0.51%
523,790
+240,290
+85% +$21M
IOVA icon
63
Iovance Biotherapeutics
IOVA
$2.02B
$49.8M 0.48%
6,425,626
+3,042,726
+90% +$19.3M
NVRO
64
DELISTED
NEVRO CORP.
NVRO
$45M 0.43%
494,900
+43,600
+10% +$3.73M
EHTH icon
65
eHealth
EHTH
$42.2M
$43.8M 0.42%
1,834,700
– –
RDUS
66
DELISTED
Radius Health, Inc.
RDUS
$43.3M 0.41%
1,122,800
+418,700
+59% +$16.4M
PVLA
67
Palvella Therapeutics
PVLA
$2B
$41.8M 0.4%
90,745
– –
IMGN
68
DELISTED
Immunogen Inc
IMGN
$41.7M 0.4%
5,450,581
+1,512,309
+38% +$10M
SGYP
69
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$39.5M 0.38%
13,621,443
-7,531,900
-36% -$25.7M
MNTA
70
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$39M 0.37%
2,109,068
– –
ONCE
71
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$38.3M 0.37%
+430,016
New +$32.7M
DERM
72
DELISTED
Dermira, Inc.
DERM
$38.3M 0.37%
1,418,873
– –
ALPN
73
DELISTED
Alpine Immune Sciences Inc
ALPN
$38.3M 0.37%
+3,298,516
New +$30.8M
RNAC icon
74
Cartesian Therapeutics
RNAC
$221M
$33.6M 0.32%
61,427
– –
DMTX
75
DELISTED
Dimension Therapeutics, Inc
DMTX
$32.4M 0.31%
5,397,698
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2017 Portfolio in Review

As of Q3 2017, OrbiMed held 153 positions worth $10.5B, up 9.7% from $9.54B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q3 2017 filing shows 17 new, 27 increased, 30 reduced and 10 closed positions. Its largest new stake was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M. The largest sale was Humana, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q3 2017 buy was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M.
  • OrbiMed added most to Aetna Inc in Q3 2017, an estimated $79.5M increase.
  • OrbiMed's biggest Q3 2017 reduction was Edwards Lifesciences, cutting an estimated $51.3M.
  • OrbiMed fully exited Humana in Q3 2017, selling an estimated $185M.
  • OrbiMed's ten largest holdings make up 35% of its $10.5B portfolio in Q3 2017.
  • OrbiMed opened 17 new positions and closed 10 in Q3 2017.
  • OrbiMed's portfolio value rose 9.7% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q3 2017, filed 14 Nov 2017.